| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000014570 |
| Receipt No. | R000016947 |
| Official scientific title of the study | Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP) |
| Date of disclosure of the study information | 2014/07/16 |
| Last modified on | 2018/08/09 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP) | |
| Title of the study (Brief title) | Denosumab or alendronate after teriparatide in GIOP patients | |
| Region |
|
|
| Condition | ||||
| Condition | glucocorticoid-induced osteoporosis (GIOP) | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Comparison of usefulness between denosumab and alendronates for the prevention of symptomatic vertebral fracture in elderly GIOP patients (more than 65 years old) with collagen vascular diseases who have done teriparatide therapy |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | Symptomatic vertebral fractures, those are determined by conventional thoracic and spinal radiographs in lateral and antero-posterior projections at any time during 3 years of this study. |
| Key secondary outcomes | Non symptomatic vertebral fractures and non-vertebral fractures deetermined by plain X-ray.
Bone mineral density values, those are measured at the lumbar spine. The serum levels of NTX, osteocalcin, 25(OH)vitamin D, etc. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Denosumab | |
| Interventions/Control_2 | alendronate | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with GIOP who have done full teriparatide therapy | |||
| Key exclusion criteria | 1)Patients who have serious renal disorder (eGFR<35ml/min or Cr>1.5mg/ml)
2)Patient who has a history of renal stone past 5 years 3)Patients with primary or secondary hyperparathyroidism 4)Patients with hyperthyroidism or hypothyroidism 5)Patients who are considered to be contraindicated for bisphosphonates or denosumab 6)Patients who are treated with warfarin or digitalis 7)Patients who have newly received drugs having influence on bone remodeling within 6 months at inclusion of the study (estriol, estradiol, Vitamin D3, Vitamin K2, SERM(Raloxifene, bazedoxifene), Calcitonin, Ipriflavone, Steroids) 8)Patients who had received bisphosphonates during teriparatide therapy 9) Patients who are thought to be inappropriate for this study by physician |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Koichi Amano |
| Organization | Saitama Medical Center,
Saitama Medical University |
| Division name | Department of Rheumatology and Clinical Immunology |
| Address | 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan |
| TEL | 0492283859 |
| amanokoi@saitama-med.ac.jp | |
| Public contact | |
| Name of contact person | Hirofumi Takei |
| Organization | Saitama Medical Center, Saitama Medical Universitity |
| Division name | Department of Rheumatology & Clinical Immunology |
| Address | 1981 Kamoda Kawagoe, Saitama 350-8550 |
| TEL | 0492283574 |
| Homepage URL | |
| takeix@saitama-med.ac.jp | |
| Sponsor | |
| Institute | Saitama Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Saitama Medical Center,
Saitama Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016947 |